Edward Dyson

Partner

London

Ed counsels public and emerging private companies, entrepreneurs, investors and investment banks on a wide range of capital markets and corporate finance transactions.

He regularly advises on IPOs, direct listings, follow-ons, de-SPACs, reverse mergers and takeovers on UK, US and European stock exchanges, domestic and cross-border public and private M&A deals, venture capital, private and growth equity investments, debt financings, joint ventures, carve-outs, and restructurings, as well as on governance, disclosure, compliance and strategic advisory matters.

His broad industry experience includes working with clients in the AI and technology, healthcare and life sciences, logistics, retail, media, marketing, financial services, energy and natural resources sectors.

He was recently recognised in The Lawyer's Hot 100 2023, by Financial News as a Rising Star of Legal Services in Europe 2023 and Financial Times at its European Innovative Lawyer Awards 2023.

  • Secondment Experience:

    • Investment Banking (Execution - Capital Markets, M&A and FCA Sponsor Team) - J.P. Morgan 
    • Depositary Receipts (Legal - ADRs / GDRs) - BNY Mellon
  • IPOs / Direct Listings / Follow-ons:

    • Ananda Pharma plc on its US OTCQB listing
    • RegTech Open Project plc on its Main Market direct listing
    • Kistos Holdings plc on its AIM direct listing
    • Zamaz plc on its Main Market direct listing and PIPE
    • OKYO Pharma Limited on its Main Market IPO, Nasdaq dual-listing, Main Market de-listing and global follow-ons
    • Panther Metals plc on Main Market follow-ons
    • Supply@ME Capital plc on Main Market follow-ons
    • Codex Acquisitions plc on its Main Market IPO
    • URA Holdings plc on its Main Market IPO
    • Hamak Gold Limited on its Main Market IPO
    • VEF AB on its First North to Nasdaq Stockholm Main Market listing step-up
    • Tiziana Life Sciences Limited on its AIM to Main Market listing step-up, Nasdaq dual-listing, Main Market de-listing and redomiciliation
    • Attica Bank S.A. on various Athens Stock Exchange follow-ons
    • e-Therapeutics plc on its US OTCQX listing
    • Mercantile Ports & Logistics Limited on AIM follow-ons
    • AccuStem Sciences Inc. on its demerger and US OTC listing
    • Farmacosmo S.p.A. on its Euronext Growth Milan IPO
    • the financial advisers on a convertible loan note financing by Hawkwing plc
    • Heptares Therapeutics Limited on the Nasdaq IPO of Centessa Pharmaceuticals plc
    • Hummingbird Ventures on the Main Market IPO of Deliveroo plc
    • the financial adviser on a placing by Nuformix plc
    • National World plc on its Main Market IPO
    • Endava plc on its NYSE IPO
    • Renalytix plc on its demerger, AIM IPO and Nasdaq dual-listing
    • the underwriters on the Nasdaq IPOs of Compass Pathways plc, Horizon Discovery plc (aborted), Bicycle Therapeutics plc, Kymab Limited (aborted) and Mereo BioPharma Group plc (aborted)
    • Autolus Therapeutics plc on its Nasdaq IPO
    • Nightstar Therapeutics plc on its Nasdaq IPO
    • Scancell Holdings plc on various AIM follow-ons
    • Realm Therapeutics plc on its direct dual-listing on Nasdaq and subsequent AIM delisting
    • B&M European Value Retail S.A. (B&M Stores), TCS Group Holdings plc (Tinkoff), "Romgaz" S.A., on their Main Market IPOs
    • the underwriters on the Main Market IPOs of Exova Group plc and Glencore plc
    • the financial advisers on the Main Market introduction of Metro Bank plc

    Public / Private M&A:

    • National World plc in connection with its final* recommended cash acquisition by Media Concierge (Holdings) Limited
    • National World plc in connection with the auction of The Telegraph Media Group
    • Nxera Pharma on its acquisition of Idorsia’s Japan and APAC (ex-China) pharmaceuticals business
    • Kistos Holdings plc on its acquisition of Mime Petroleum A.S.
    • National World plc on its possible offer for Reach plc
    • Kistos plc on its possible offer for Serica Energy plc
    • Pires Investments (now Mindflair) plc on its proposed takeover by Tern plc
    • Realm Therapeutics plc on its recommended takeover by Essa Pharma Inc.
    • MightyHive Inc. on its acquisition by S4 Capital plc

    De-SPACs / Reverse Takeovers:

    • Technologies New Energy plc on its Main Market de-SPAC of Technologies New Energy S.A.
    • Atlas Metals Group plc on its (aborted) Main Market reverse takeover of Compagnie Minière de Oumejrane 
    • Kistos plc on its reverse takeover of Tulip
    • National World plc on its reverse takeover of JPI Media
    • VNV Global AB on the Nasdaq de-SPACs of Swvl with Queen's Gambit Growth Capital and Gett with Rosecliff Acquisition Corp I
    • Kinnevik AB on the NYSE de-SPAC of Babylon Health with Alkuri Global Acquisition Corp.
    • RockRose Energy plc on its reverse takeovers of certain North Sea interests acquired from Marathon Oil and Idemitsu Petroleum

    Private Capital:

    • A financial investor on a Seed financing round for a UK fintech
    • A tech business on its Series A financing
    • FOMTECH Limited (Floww) on its Series B and C financings
    • Metro Africa Xpress Inc. on its Series B financing

    Strategic Advisory:

    • capAI plc on corporate matters
    • Floww on its strategic partnership with London Stock Exchange Group to create a global private capital market
    • Force Over Mass Capital LLP on partnership matters
    • Round Group Limited on the establishment of its Apex influencer and creator business
    • Nxera Pharma on its collaboration and licensing agreements with Neurocrine Biosciences Inc., Eli Lilly and Co., Viatris and another global biomedical company

    Please note: Ed's experience includes that prior to joining Orrick.